NEW DRUGS FOR LEUKEMIA
March 15th/17th, 2012
Palazzo del Principe
Genoa – Italy
Preliminary Program – First Announcement
Day 1 – Thursday, March 15th, 2012
04.30 p.m. – 05.00 p.m. Registration
05.00 p.m. – 06.30 p.m. Welcome
Marco Gobbi (Dep. of Hematology and Oncology IRCCS AOU San
Martino-IST Genova, Italy)
Moderators:
Fabrizio Pane (Hematology Dept., Policlinico Federico II, Napoli, Italy)
Antonio Cuneo (Hematology Dept., University of Ferrara, Italy)
Starting from new genomic insights
Gene function and regulation (Giulio Superti Furga, Research Center for
Molecular Medicine, Wien)
The regulation of transcription and transduction (Sergio Ferrari, Dept. of
Biomedical Science, Modena, Italy)
Receptors and signaling (Daniela Cilloni – Dept. of Clinical and Biological
Sciences, Torino, Italy)
06.30 p.m.– 07.15 p.m. Leukemia stem cells: new paradigm for target therapy
Pier Giuseppe Pelicci (Dept. of Experimental Oncology, European
Institute of Oncology, Milan, Italy)
07.15 p.m.
Welcome Ceremony
1
Day 2 – Friday, March 16th, 2012
08.30 a.m. - 10.30 a.m. SESSION I - Molecular diagnosis and prognosis
Moderators:
Michele Baccarani (Institute of Hematology “L. and A. Seràgnoli”,
Bologna, Italy)
Francesco Lauria (MD Professor of Hematology and Head of Dept. of
Hematology & Transplant - University of Siena, Italy)
08.30 a.m.– 08.40 a.m. INTRODUCTION to the lecture
Michele Baccarani (Institute of Hematology “L. e A. Seràgnoli”, Bologna,
Italy)
08.40 a.m. – 09.10 a.m. LECTURE: New damage related to leukemia
Charles Mulligan (St. Jude Hospital, Memphis, USA)
09.10 a.m.– 09.30 a.m. Diagnostic and predictive biomarkers for MDS
Mario Cazzola (Dept. of Hematology-Oncology,Policlinico San Matteo,
Pavia, Italy)
09.30 a.m.– 09.50 a.m. Diagnostic and predictive biomarkers for AML
Maurizio Miglino (Dept. of Hematology-Oncology, University of Genoa,
Italy)
09.50 a.m.– 10.10 a.m. Diagnostic and predictive biomarkers for ALL
Ilaria Iacobucci (Institute of Hematology “L. and A. Seràgnoli”, Bologna,
Italy)
10.10 a.m.– 10.30 a.m. Discussion
10.30 a.m.– 10.50 a.m. Coffee Break
10.50 a.m. – 12.50 a.m. SESSION II - Leukemia genes as target
Moderators:
Giuseppe Leone (Dept.s of Hematology and Pathology, Universita'
Cattolica, Rome, Italy)
Giorgina Specchia (Hematology Dept. Policlino Bari, Italy)
2
10.50 a.m.– 11.10 a.m. INTRODUCTION: Monosomy as general Pathogenetic Mechanism of
Leukemia
Clelia Tiziana Storlazzi (Dept. of Genetics and Microbiology Bari, Italy)
11.10 a.m. – 11.30 a.m. Aurora and Polo Kinases
Cristina Papayannidis (Institute of Hematology "L. and A. Seràgnoli",
Bologna, Italy)
11.30 a.m. – 11.50 a.m. NOTCH Mutation in Hematological Malignancies
Gianluca Gaidano (Hematology Dept., Novara, Italy)
11.50 a.m. – 12.10 a.m. Nutlin and other HDM2 on clinical setting
Giovanni Martinelli (Hematology Associated Professor Dep.of
Hematology “L. e A. Seràgno li”, Alma Mater Studiorum Università
di Bologna, Italy)
12.10 a.m.– 12.30 a.m. Targeting leukemia stem cell: Anti-Hedeghog pathways strategies
against LSC
Giuseppe Saglio (Dept. of Clinical and Biological Sciences, Torino, Italy)
12.30 a.m. – 12.50 a.m. Discussion
12.50 a.m.– 02.00 p.m. Lunch
02.00 p.m. – 03.00 p.m. SESSION III - Gene modifier
Moderators:
Andrea Bacigalupo (Hematology Dept., San Martino Hospital, Genoa,
Italy)
Giovanni Pizzolo (Division of Hematology, Dept. of Medicine University of
Verona, Italy)
02.00p.m. – 02.20 p.m. Epigenetic check of normal and leukemic hematopoiesis: new insight
Maria Teresa Voso (Hematology Dept., Policlinico Gemelli, Roma, Italy)
02.20 p.m. – 02.40 p.m. Leukemia 20-30%: new entity for new therapy
Domenico Russo (Hematology Dept., Brescia, Italy)
02.40 p.m.– 03.00 p.m. Gene modifier: is the microenvironment the therapeutic target?
Giuseppe Visani (Hematology Dept., Pesaro, Italy)
03.00 p.m. – 03.20 p.m. Coffee Break
3
03.20 p.m.-05.50 p.m. SESSION IV - New Purine Analogs and Signal
Transduction inhibitors
Moderators:
Gianpietro Semenzato (Hematology Dept. , University of Padua, Italy)
Mario Petrini (Hematology Dept., University of Pisa, Italy)
03.20 p.m. – 03.50 p.m. Lecture – The lesson of NPM or other genetic lesions in AML
Brunangelo Falini (Hematology Dept., Perugia, Italy)
03.50p.m.– 04.10 p.m. INTRODUCTION: New biomarker for optimal use of Clofarabine
Andrea Pession (U.O. Pediatrics, S. Orsola Hospital, Bologna, Italy)
04.10 p.m.– 04.30 p.m. Tosedostat as model of Aminopeptidase modifier
Marco Gobbi (Dep. of Hematology and Oncology IRCCS AOU San
Martino-IST Genova, Italy)
04.30 p.m. – 04.50 p.m. Nelarabine in Adult ALL
Felicetto Ferrara (Hematology Dept., Cardarelli Hospital, Napoli, Italy)
04.50 p.m. – 05.10 p.m. AKT2axis and MTOR inhibitor
Sergio Amadori (Hematology Dept., Policlinico Tor Vergata, Roma, Italy)
05.10 p.m. – 05.30 p.m. Fluda associated regimens: New standard of care?
Anna Candoni (Clinica Ematologica, Udine, Italy)
05.30 p.m. – 05.50 p.m. Discussion
Day 3 – Saturday, March 17th, 2012
08.30 a.m. - 10.00 a.m. SESSION V – FLT3 and surround targets
Moderators:
Alberto Bosi (Hematology Dept. , University of Florence, Italy)
Angelo Michele Carella (Hematology Dept., University San Martino,
Genoa, Italy)
08.30 a.m. – 09.00 a.m. LECTURE: New drugs in MRC studies
Alan Burnett (Hematology Dept., Cardiff, UK)
4
09.00 a.m. – 09.20 a.m. New FLT3 inhibitors: AC220
Philippe Rousselot (Université Versailles Saint-Quentin-en-Yvelines,
France)
09.20 a.m. – 09.40 a.m. Ponatinib a new BCR-ABL and FLT3 inhibitor
Gianantonio Rosti (Hematology Dept., University of Bologna, Italy)
09.40 a.m. – 10.00 a.m. PKC412 as front line therapy
Adriano Venditti (Hematology Dept. Tor Vergata University Hospital,
Roma, Italy)
10.00 a.m.– 10.20 a.m. Coffee Break
10.20 a.m.-12.20 a.m. SESSION VI – Myeloproliferative diseases and new
molecular based approaches
Moderators:
Alessandro Rambaldi (Hematology Dept. , Ospedali Riuniti di Bergamo,
Italy)
Giuseppe Leone (Hematology Dept. Policlinico Gemelli, Roma, Italy)
10.20 a.m.– 10.40 a.m. Introduction: JAK Inhibitor New Era
Francesco Frassoni (Hematology Dept., San Martino Hospital, Genoa,
Italy)
10.40 a.m. – 11.00 a.m. “JAK2 positive” leukemias a new entity
Charles Mullighan (Pathology Dept., St. Jude Children's Research
Hospital, Memphis, USA)
11.00 a.m. – 11.20 a.m. JAK2 inhibitors: The COMFORT clinical trials
Nicola Vianelli (Hematology Dept. "L. and A. Seràgnoli", Bologna, Italy)
11.20 a.m. – 11.40 a.m. Early clinical development of drugs in MF
Giovanni Barosi (Unit of Clinical Epidemiology and Center for the Study
of Myelofibrosis, Policlinico S. Matteo, Pavia, Italy)
11.40 a.m. – 12.00 a.m. A selective JAK2 mutated inhibitors: we really need?
Alessandro Vannucchi (Hematology Dept, Florence, Italy)
12.00 a.m. – 12.20 a.m. Take home messages
Giovanni Martinelli (Hematology Associated Professor Dep.of
Hematology “L. e A. Seràgno li”, Alma Mater Studiorum Università
di Bologna, Italy)
12.20 a.m.
Lunch
5